NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for NTERA-2 Cells (Embryonal Carcinoma Cells, CRL-1973)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
Reproducible transfection results
- Download in vitro NTERA2 transfection protocol: [PDF]
Download PowerPoint presentation for NTERA2 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 76% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NTERA2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NTERA-2 Cell Line:
The NTERA-2 cl.D1 cell line was established from the parental NTERA-2 cell line (originally established in 1980) after a xenograft of a 22-year-old Caucasian male patient. The patient suffered from malignant pluripotent embryonic carcinoma of the testis. This cell line has unique properties, making it useful for study of certain types of testicular cancer. These cells exhibit high activity expression of N-myc oncogene. This cell line contains untreated cells with resistance to HCMV, and HIV-1. NTERA-2 cl.D1 exhibits an epithelial-like morphology, though there is more variety than in other cell lines due to the high differentiation of these cells.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NTERA-2 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A in NTERA-2 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NTERA-2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6875)
- 1.5 ml (Catalog #6876)
- 1.5 ml CRISPR (Catalog #2186)
- 8.0 ml (Catalog #7075)